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Abstract
Metformin, a mainstay drug used clinically for over 60 years, improves insulin sensitivity 
and is widely prescribed for type 2 diabetes mellitus. Since population-based studies have 
suggested that metformin decreases the incidence of cancer and cancer-related mortality 
in patients with diabetes, metformin has attracted attention in cancer research as well. 
Endometrial cancer （EC） is the most common gynecological cancer and exhibits the strongest 
association with obesity and insulin resistance, and as such, is hypothesized as a suitable target 
cancer for metformin evaluation. 
In the in vitro experiment, metformin suppressed EC cell proliferation via AMPK-
dependent and independent pathways, as in other cancer cell lines. Metformin also showed an 
additive effect on cell proliferation when administered in combination with anticancer drugs. 
Since the dose that was necessary to suppress cell proliferation in vitro was notably higher 
than the serum concentration in metformin-administered patients, we next examined whether 
a clinical dose of metformin was effective in patients. Preoperative metformin treatment 
decreased serum-stimulated DNA synthesis and significantly reduced Ki-67 and topoisomerase 
IIα levels in endometrial tissues, indicating reduced growth-supporting potential in the serum 
of patients with EC. Collectively, metformin may act both directly and indirectly, with both 
pathways contributing to its anti-neoplastic activity. In a clinical setting, we conducted a phase 
II study of medroxyprogesterone （MPA） in combination with metformin as a fertility-sparing 
treatment for patients with atypical endometrial hyperplasia or EC. Combining metformin with 
MPA reduced relapse after remission and improved patient metabolic status. Following the trial, 
we have initiated a prospective randomized, open, blinded-endpoint, dose-response trial （phase 
IIb） of MPA plus metformin （jRCT 2031190065） to verify an appropriate metformin dose in a 
fertility-sparing treatment, which is ongoing. 
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Ⅰ．Introduction
 Endometrial cancer （EC） is the most common 
gynecological cancer, and the fourth most common 
cancer among women in the US［1］. Its prevalence in 
Japan has increased almost fivefold over the past two 
decades. Among all cancers, EC shows the strongest 
association with obesity, with a 5 kg/m2 increase in body 
mass index （BMI） strongly associated with EC at a 
risk ratio of 1.59 with 95 % confidence interval （CI） of 
1.50-1.68 （P＜0.0001）［2］. Moreover, the risk for EC 
in women with BMI ≥ 25 is two to four times greater 
than in women with BMI＜25［3］.  Additionally, the 
prevalence of hyperinsulinemia and insulin resistance 
（IR） is high among patients with EC regardless of their 
obesity status［4］. EC risk also increases with diabetes 
mellites （DM）［5,6］. This association can be largely 
accounted for by obesity. 
 Mechanisms that link excess weight and cancer risk 
have not been fully understood. Nonetheless, insulin 
and the insulin-like growth factor （IGF） axis are the 
most studied candidates. Insulin and IGF-1 signaling via 
the insulin and IGF-1 receptors, respectively, promote 
cellular proliferation and inhibit apoptosis via the 
phosphoinositide 3 kinase/AKT/mammalian target of 
rapamycin （mTOR） pathway and mitogen-activated 
protein kinase （MAPK） pathway in many tissue types
［7］. Metformin is a biguanide widely prescribed to treat 
type 2 DM that inhibits complex I of the mitochondrial 
electron transport chain［8］and stimulates adenosine 
monophosphate-dependent kinase （AMPK）［9］, which 
reduces gluconeogenesis while enhancing glucose 
uptake in skeletal muscles to reduce insulin levels. 
Recently, metformin has attracted attention in cancer 
research since population-based studies suggest that it 
decreases the incidence of cancer and cancer-related 
mortality in patients with diabetes. Multiple meta-
analyses have reported that metformin is associated 
with a decreased risk of breast, colon, liver, pancreas, 
prostate, endometrial, and lung cancer［10,11］. 
 We hypothesized that metformin could be useful 
for EC prevention and treatment because of its direct 
and indirect actions improving insulin resistance and 
abnormal glucose tolerance. Therefore, we conducted 
basic and clinical research with the aim of applying 
metformin to the treatment of endometrial cancer. 
Ⅱ． Insulin resistance, diabetes, and 
endometrial cancer 
 A common link between obesity and EC is 
classically but not fully explained by unopposed 
estrogen［12］. Estrogen is produced via aromatization 
in peripheral adipocytes and does not encounter 
antagonization by progestin, and is associated with 
increased risk of EC［13,14］. However, unopposed 
estrogen alone cannot fully explain the risk of EC, and 
insulin resistance is also believed to be involved. 
 A high prevalence of IR and abnormal glucose 
metabolism in patients with EC has been reported 
at 36-67%［4,15,16］. The marked difference in IR 
prevalence in the previous reports is thought to be race-
dependent, where IR occurs more frequently among 
Hispanic women［4］, for example. There is an apparent 
association between DM and increased risk of EC［5,6］, 
and the prevalence of pre existing DM in patients with 
EC is around 15.5%-25%［17-19］. However, little is 
known about the exact prevalence of abnormal glucose 
metabolism, since not all studies examined glucose 
tolerance. 
 We evaluated 279 patients with EC among Japanese 
women［16］, among whom 55 （20.1%） were already 
diagnosed with DM. A 75-g oral glucose tolerance test 
was performed on the remaining 225 patients. Impaired 
fasting glucose, impaired glucose tolerance, and DM 
were newly identified in 7 （2.5%）, 69 （24.7%）, and 
33 （11.8%） patients, respectively. Eventually, more 
than half of EC patients （58.4%） were categorized to 
be in the pre-DM or DM stage, and IR was identified 
in 144 （51.6%）. In each age group, BMI ≥ 25 kg/m2 
was 71% in patients＜40 years old, 58% in patients 
41-59 years old, 56% in patients 51-59 years old, and 
17% in patients＞60 years old in type I EC patients 
alone. Patients＜40 years of age were more likely to 
be obese and have IR. Summarily, abnormal glucose 
metabolism, IR, and obesity were highly prevalent in 
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patients with EC. These results indicate that physicians 
should consider a patient’s metabolic status during the 
postoperative management of EC patients. 
Ⅲ． In vitro effect of metformin on 
endometrial cancer cells 
 Metformin is an AMPK-dependent growth inhibitor 
in breast cancer［20］, and similar antiproliferative 
effects have been demonstrated in several cancer cell 
lines. We treated established endometrial cancer cells 
with metformin, and similarly observed that cell growth 
substituted by thymidine uptake was suppressed in 
a concentration-dependent manner［21］（Fig. 1A）. 
Flow cytometry indicated that metformin caused 
a significant increase in the number of cells in the 
G1 phase of the cell cycle （Fig. 1B）, where the cell 
cycle was arrested in G0/G1 accompanied by a strong 
decrease in cyclin D1 and phospho-RB and increased 
expression of p27 Kip1 proteins. In addition, metformin 
induced phosphorylation of AMPKα and decreased 
phosphorylation of S6K1 and ERK1/2 （Fig. 2）. 
However, inhibition of the AMPK pathway via siRNA-
mediated AMPKα knockdown did not prevent the 
antiproliferative effect of metformin, suggesting that its 
effects on the cell cycle are independent of the AMPK 
pathway （unpublished）. 
 We also tested metformin in combination with 
cisplatin and adriamycin and found it to have additive 
effects such as increased apoptosis and suppression of 
thymidine uptake［22］. However, the antitumor effect of 
metformin in combination with cisplatin was attenuated 
under hypoxia compared to normoxia （Fig. 3）. Mito 
Tracker staining indicated that metformin reduced 
mitochondrial fragmentation, indicating that metformin 
caused morphological and functional changes to the 
mitochondria. The additive effects of metformin on 
cisplatin-induced inhibition of cell proliferation were 
attenuated under hypoxic conditions, while metformin 
compromised mitochondrial structure and function. 
Fig. 1　Metformin inhibits the proliferation of cells 
in a dose-dependent manner. （A） Ishikawa cells and 
HEC IB cells were treated with metformin for 48 h. 
Cell proliferation was measured using the thymidine 
incorporation assays. Results are presented as means ± 
standard errors of the mean. Asterisks indicate significant 
differences compared with metformin-free controls （P＜
0.05, Mann-Whitney U-test）. From Mitsuhashi et al., 
modified with permission［21］. （B） Flow cytometry 
analysis of Ishikawa cells after 24 h treatment with 5 or 10 
mM metformin. The cells in the G1 phase of the cell cycle 
is indicated. After the addition of metformin, G1 cells 
increased by 18.6% in those treated with 5 mM metformin 
and 23% in those treated with 10 mM metformin compared 
to 16.8% in the control. 
Fig. 2　Western blotting for MAPK·AMPK·mTOR 
signaling pathways and cell cycle proteins showing the 
dose-dependent change. Proteins extracted from Ishikawa 
cells that had been exposed to metformin （1-20 mM） for 
24 h were subjected to western blotting for the analysis of 
cyclin D1 expression and the evaluation of AMPK, S6K1, 
ERK1/2, and Rb phosphorylation. 
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Ⅳ． In vivo effect of metformin on 
endometrial cancer cells 
 A number of unanswered questions remain prior 
to a clinical application. First is that the metformin 
concentration to suppress cell growth in vitro studies 
was much higher than the reported serum concentration 
of metformin in patients with orally administered 
metformin for DM （1mM vs. 13µM by Cmax from 
interview form）. Can such a low concentration of 
metformin reduce EM cell growth in vivo? Accordingly, 
we carried out window-of-opportunity studies using 
scheduled preoperative administration of clinical 
doses［21］by administering 1500-2250 mg/day to 
31 endometrial cancer patients for 4-6 weeks prior to 
surgical treatment. Preoperative metformin treatment 
significantly reduced Ki-67 labeling indices with a mean 
proportional decrease of 21.2% （95% CI 16.1-26.3; P
＜.0001） and topoisomerase IIαlabeling indices with a 
mean proportional decrease of 20.4% （95% CI, 13.0-
Fig. 3　Effect of combined metformin and cisplatin 
treatment on thymidine incorporation in Ishikawa cells 
cultured at different O2 levels. （A） In cells cultured under 
normoxic conditions （21% O2）, higher concentrations 
of metformin resulted in a greater reduction in thymidine 
incorporation relative to cells treated with cisplatin only. 
（B） The additive effects of metformin and cisplatin were 
attenuated under hypoxic conditions （1% O2）. Data are 
shown as mean ± standard error of six samples from three 
independent experiments. *P＜0.005 and **P＜0.001. 
From Uehara et al., modified with permission［22］. MET: 
metformin, CDDP: cisplatin. 
Fig. 4　Preoperative metformin administration reduces 
proliferative activity and alters cell proliferation 
signaling. （A） Preoperative metformin administration 
decreased immunostaining of Ki-67 and topoisomerase 
IIα in endometrial cancer tissues. Representative changes 
in immunostaining are shown for paired specimens. The 
change in labeling indices, expressed as a percentage of 
positively stained nuclei among a total of 500 nuclei, are 
shown for each pair and evaluated using the Wilcoxon 
signed-rank test. （B） Cell signaling molecules in 
endometrial cancer tissues were detected by western 
blotting, quantitated by densitometry, and normalized to 
β-actin. Pre: before the commencement of metformin 
treatment; Post: after metformin treatment. From 
Mitsuhashi et al., modified with permission［21］.  
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reduces cancer proliferative activity by changing the 
endocrine environment. 
 We next investigated the effect of metformin on the 
expression of protein phosphatase 2A （PP2A） in EC 
tissues using immunohistochemistry［23］. Preoperative 
metformin treatment resulted in significantly 
reduced PP2A expression. Additionally, metformin 
administration resulted in significantly reduced PP2A 
regulatory subunit 4 （PPP2R4） mRNA expression 
（mean proportional decrease of 31.3% with 95% CI of 
13-50; P＝.039） in EC tissues. PPP2R4 knockdown 
reduced proliferation and induced apoptosis by 
activating caspases 3/7 in HEC265 and HEC1B cells. 
However, metformin was not capable of directly altering 
PPP2R4 mRNA expression in EC cancer cell lines. 
These findings indicate that metformin downregulated 
PPP2R4 expression indirectly in patients with EC, 
which might lead to apoptosis of endometrial cancer 
cells. 
Ⅴ． Application of metformin in fertility-
sparing treatment for patients with 
atypical endometrial hyperplasia and 
endometrial cancer 
 Progestin therapy is one of the most popular 
treatment options for preserving fertility in patients 
with atypical endometrial hyperplasia （AEH） and EC. 
The guidelines of the National Comprehensive Cancer 
Network （Version 3.2019） and the European Society of 
Gynecological Oncology Task Force for fertility-sparing 
treatment recommend progestin therapy for patients 
with AEH and EC who wish to preserve fertility［24］. 
Although fertility-sparing treatments have high rates of 
remission, they are also associated with high rates of 
relapse［25,26］. Based on our results of in vitro and in 
vivo analyses, metformin use may be a promising therapy 
for controlling recurrence after progestin treatment. In 
our phase II study of medroxyprogesterone （MPA） 
plus metformin as a fertility-sparing treatment for AEH 
and EC patients, we found that metformin inhibits 
disease relapse after remission （UMIN 000002210）
［27］. In this trial, patients received a daily oral dose 
27.8; P＜.0001） （Fig. 4A）. Phospho-ribosomal protein 
S6 and phospho-extracellular signal-regulated kinase 1/2 
were significantly decreased, and phospho-adenosine 
monophosphate activated protein kinase and p27 were 
significantly increased （Fig. 4B）. 
 We then evaluated metformin concentration in serum 
and endometrial tissues of patients taking a clinical dose 
and found quite low concentrations, at 6.8-18.1 µM in 
serum and 1.2-5.1 µmol/kg in endometrium 2 h after 
administration （likely representative of Cmax）. Since the 
minimum concentration required to suppress growth 
is approximately 1 mM in vitro, these concentrations 
represent＜1/400 of the estimated required dose. 
 DNA synthesis-stimulating activity in patient 
serum decreased significantly after metformin 
administration from pre-treatment levels （Fig. 5）. 
Preoperative metformin use also caused a significant 
decrease in circulating factors （including insulin, 
glucose, insulin-like growth factor 1, and leptin）, 
with oral administration decreasing insulin and IGF-
1 by approximately 40% and 15%, respectively. These 
findings support the possibility that metformin indirectly 
Fig. 5　Humoral factors were responsible for the 
stimulatory action of metformin on thymidine uptake. 
Thymidine uptake （DNA synthesis） activity of Ishikawa 
cells is measured in the presence of serum collected from 
patients before and during metformin treatment. Serum 
samples during metformin treatment were collected 
before and 2 h after a 75 g oral glucose tolerance test. 
Connecting lines represent paired samples obtained from 
the same patients. OGTT, oral glucose tolerance test; N.S., 
not significant. From Mitsuhashi et al., modified with 
permission［21］. 
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 Following this trial, we reported long-term outcomes 
for patients with AEH and EC on MPA plus metformin
［28］. Ninety-seven percent of patients treated with MPA 
and metformin （61/63） achieved CR within 18 months. 
Metformin significantly reduced relapse in comparison 
to a historical control of 24 patients treated only with 
MPA. Relapse-free survival at 3 years in patients with 
EC treated with MPA plus metformin and MPA alone 
was 79.7% and 43.0%, respectively （P＝.025 Fig. 
7）. Notably, metformin may be more efficacious for 
patients with BMI≥25 kg/m2, as these patients showed 
significantly better prognoses than patients with BMI＜
25 kg/m2 （odd ratio 0.27; 95% CI, 0.08-0.88; P＝0.03）. 
 We recently initiated a prospective randomized, 
open, blinded-endpoint design, dose-response trial 
（phase IIb） of MPA plus metformin in fifteen 
institutions of Japan （jRCT 2031190065） （Fig. 8） 
in order to define the appropriate metformin dose 
in a fertility-sparing treatment involving combined 
metformin and MPA among patients with AEH and 
EC and to further investigate long-term efficacy and 
safety. Patients were randomized to receive MPA only, 
MPA + 750 mg/day metformin, or MPA + 1500 mg/
day metformin taken simultaneously. If patients achieve 
remission during MPA treatment, metformin therapy 
will be continued until conception or disease recurrence 
in MPA +metformin group. The primary endpoint of 
the study is a 3-year relapse-free survival rate, which 
would indicate the achievement of remission without 
recurrence 3 years from the entry date of study for all 
subjects. Secondary endpoints include the relapse-free 
of 400 mg MPA for 24-36 weeks and metformin at 
an initial dose of 750 mg/day （increased weekly by 
750 mg up to 2250 mg/day in the absence of adverse 
effects） administered concurrently from the initiation 
of treatment until pregnancy was confirmed. Of the 36 
patients, 29 （81%） achieved a complete response （CR）, 
with three （10%） relapsing during a median follow-up 
period of 38 months （Fig. 6）. Metformin additionally 
prevented weight gain induced by MPA and improved 
insulin resistance. 
Fig. 6　Kaplan-Meier curves for relapse-free survival 
in patients who achieved remission after treatment with 
metformin plus medroxyprogesterone acetate. AEH, 
atypical endometrial hyperplasia; EC, endometrial cancer. 
From Mitsuhashi et al., modified with permission［27］. 
Fig. 8　Study design of a prospective randomized, 
open, blinded-endpoint design, dose-response trial 
（phase IIb） of MPA plus metformin. See the text for 
detailed explanation. 
Fig. 7　Relapse-free survival of patients with 
endometrial cancer treated with metformin plus 
medroxyprogesterone acetate （MPA） compared with 
historical controls treated with MPA alone. From 
Mitsuhashi et al., modified with permission［28］.  
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6 ） Zhang ZH, Su PY, Hao JH, Sun YH. （2013） The role of 
preexisting diabetes mellitus on incidence and mortality 
of endometrial cancer: a meta-analysis of prospective 
cohort studies. Int J Gynecol Cancer 23, 294-303. 
7 ） Calle EE, Kaaks R. （2004） Overweight, obesity 
and cancer: epidemiological evidence and proposed 
mechanisms. Nat Rev Cancer 4, 579-91. 
8 ） Owen MR, Doran E, Halestrap AP. （2000） Evidence 
that metformin exerts its antidiabetic effects through 
inhibition of complex 1 of the mitochondrial respiratory 
chain. Biochem J 348, 607-14. 
9 ） Zhou G, Myers R, Li Y, et al. （2001） Role of AMP-
activated protein kinase in mechanism of metformin 
action. J Clin Invest 108, 1167-74. 
10） Evans JM, Donnelly LA, Emslie-Smith AM, Alessi 
DR, Morris AD. （2005） Metformin and reduced risk of 
cancer in diabetic patients. BMJ 330, 1304-5. 
11） Heckman-Stoddard BM, DeCensi A, Sahasrabuddhe 
VV, Ford LG. （2017） Repurposing metformin for the 
prevention of cancer and cancer recurrence. Diabetologia 
60, 1639-47. 
12） Key TJA, Pike MC. （1988） The dose-effect relationship 
between ‘unopposed’ oestrogens and endometrial 
mitotic rate: Its central role in explaining and predicting 
endometrial cancer risk. Br J Cancer 57, 205-12. 
13） Crosbie EJ, Zwahlen M, Kitchener HC, Egger M, 
Renehan AG. （2010） Body mass index, hormone 
replacement therapy, and endometrial cancer risk: a meta-
analysis. Cancer Epidemiol Biomarkers Prev 19, 3119-
30. 
14） Potischman N, Hoover RN, Brinton LA, et al. （1996） 
Case-Control Study of Endogenous Steroid Hormones 
and Endometrial Cancer. J Natl Cancer Inst 88, 1127-35. 
15） Berstein LM, Kvatchevskaya JO, Poroshina TE, et 
al. （2004） Insulin resistance, its consequences for 
the clinical course of the disease, and possibilities of 
correction in endometrial cancer. J Cancer Res Clin 
Oncol 130, 687-93. 
16） Mitsuhashi A, Uehara T, Hanawa S, Shozu M. （2017） 
Prospective evaluation of abnormal glucose metabolism 
and insulin resistance in patients with atypical 
endometrial hyperplasia and endometrial cancer. Support 
Care Cancer 25, 1495-501. 
17） Zanders MM, Boll D, van Steenbergen LN, van de Poll-
Franse LV, Haak HR. （2013） Effect of diabetes on 
endometrial cancer recurrence and survival. Maturitas 74, 
37-43. 
18） Nevadunsky NS, Van Arsdale A, Strickler HD, et al. 
（2014） Metformin use and endometrial cancer survival. 
Gynecol Oncol 132, 236-40. 
19） Ko EM, Walter P, Clark L, et al. （2014） The complex 
triad of obesity, diabetes and race in Type I and II 
endometrial cancers: prevalence and prognostic 
significance. Gynecol Oncol 133, 28-32. 
20） Zakikhani M, Dowling R, Fantus IG, et al. （2006） 
survival rate, the overall response rate to MPA therapy, 
the conception rate following treatment, the outcome of 
pregnancy, the toxicity evaluation, and the changes in IR 
and BMI. This study is presently ongoing. 
Ⅵ．Conclusion
 The direct and indirect effects of metformin on 
EC contribute to its anti-neoplastic activity. Due to its 
observed metabolic involvement, EC may be one of 
the best candidate cancers for metformin use. Studies, 
including ours, have indicated the potential uses of 
metformin against EC in combination with anticancer 
chemotherapeutic drugs and progestins. In the future, 
in addition to using fertility-sparing therapy, metformin 
may be applied in postoperative maintenance therapy 
for EC or as a preventative measure against endometrial 
carcinogenesis. 
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